Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 5 of 99

  1. 2223-001

    KYOWA KIRIN AUSTRALIA PTY LTD

    T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)

    phase 1 other active

    1 trial

  2. 22231

    Bayer AG

    Advanced solid tumors, Non-small cell lung cancer

    phase 1 other active

    1 trial

  3. 22262

    Bayer AG

    hepatocellular carcinoma (HCC)

    phase 1 other active

    1 trial

  4. 22265

    Bayer AG

    Coagulopathy, Sepsis

    phase 1 other active

    1 trial

  5. 222778

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  6. 22342

    Bayer AG

    Heart failure in children

    phase 1 other active

    1 trial

  7. 22375

    Bayer AG

    Prevention of ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack in combination with antiplatelet therapy

    phase 1 other active

    1 trial

  8. 22534

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  9. 22537

    Bayer AG

    Soil-transmitted helminth infection, Onchocerciasis (river blindness)

    phase 1 other active

    1 trial

  10. 22597

    Bayer AG

    Chronic kidney disease, Coronary artery disease

    phase 1 other active

    1 trial

  11. 22598

    Bayer AG

    Chronic Kidney Disease, Arterial hypertension

    phase 1 other active

    1 trial

  12. 22600

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  13. 22665

    Bayer AG

    Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack

    phase 1 other active

    1 trial

  14. 22676

    Bayer AG

    Advanced solid tumors harboring KRAS G12C mutation

    phase 1 other active

    1 trial

  15. 22700

    Bayer AG

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  16. 22723

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial

  17. 22806

    Bayer AG

    atrial fibrillation, transient ischemic attack (TIA), ischemic stroke

    phase 1 other active

    1 trial

  18. 22819

    Bayer AG

    Cardiac arrhythmia

    phase 1 other active

    1 trial

  19. 22967

    Bayer AG

    Vasodilatory shock

    phase 1 other active

    1 trial

  20. 23U-0502

    Disc Medicine

    Metastatic colorectal cancer

    phase 1 other active

    1 trial

  21. 24EU-Lip03

    The George Institute

    None. Healthy subjects

    phase 1 other active

    1 trial

  22. 250 mg capsule

    LEXICON PHARMACEUTICALS, INC.

    Irritable Bowel Syndrome

    phase 1 small molecule completed

    1 trial

  23. 25mcg rhPTH(1-84)

    Takeda

    Hypoparathyroidism

    phase 1 small molecule completed

    1 trial

  24. 262SP101(ION464-CS1)

    IONIS PHARMACEUTICALS INC

    Multiple System Atrophy

    phase 1 other active

    1 trial

  25. 2693-CL-2101

    Astellas Pharma GmbH

    Hot Flush

    phase 1 other active

    1 trial

  26. 277HV101

    Biogen

    Spinal muscular atrophy

    phase 1 small molecule active

    1 trial

  27. 2X-121 and dovitinib

    Allarity Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule on hold

    1 trial

  28. 2mg INO-5150 and electroporation device CELLECTRA®-5P

    INOVIO PHARMACEUTICALS, INC.

    Prostate Cancer

    phase 1 mab completed

    1 trial

  29. 3-dimensional conformal radiation therapy

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 1 other active

    1 trial

  30. 30 mg dexlansoprazole capsules manufactured at TOB

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  31. 300 mg LX4211 (150 mg tablets)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  32. 300 mg [C14] CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  33. 300134

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  34. 300141

    HALEON AUSTRALIA PTY LTD

    Healthy volunteers, therapeutic indication not studied

    phase 1 other active

    1 trial

  35. 300163

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  36. 304 injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    CD20 Positive B Cell NHL

    phase 1 small molecule active

    1 trial

  37. 31254

    United Therapeutics Europe Ltd

    HIE - Perinatal Hypoxic - Ischemic Encephalopathy

    phase 1 small molecule completed

    1 trial

  38. 3135003

    Orion Laboratories Pty.

    Parkinson desease

    phase 1 other active

    1 trial

  39. 3135004

    Orion Laboratories Pty.

    Parkinson disease

    phase 1 other active

    1 trial

  40. 3137001

    Orion Laboratories Pty.

    short-term treatment of insomnia

    phase 1 other active

    1 trial

  41. 323-201-00009

    Otsuka Beijing Research Institute

    Tuberculosis

    phase 1 other active

    1 trial

  42. 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Abuse

    phase 1 small molecule terminated

    1 trial

  43. 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 1 small molecule terminated

    1 trial

  44. 400 mg Cannabidiol

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Pain

    phase 1 small molecule active

    1 trial

  45. 400 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  46. 400314

    HALEON AUSTRALIA PTY LTD

    For the local, symptomatic treatment of pain in acute bruises, strains, or sprains due to blunt trauma, e.g., sports and accident injuries

    phase 1 other active

    1 trial

  47. 4010-01-001

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  48. 42756493BLC1003

    Janssen-Cilag International N.V.

    Localized Bladder Cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.